Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Multiple sclerosis symptom recrudescence at the end of the natalizumab dosing cycle.
CD4 cell response to interval therapy with natalizumab.
MRI in multiple sclerosis: an intra-individual, randomized and multicentric comparison of gadobutrol with gadoterate meglumine at 3 T.
Neuromyelitis optica with very late onset.
FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
Regulatory T, natural killer T and γδ T cells in multiple sclerosis and chronic fatigue syndrome/myalgic encephalomyelitis: a comparison.
De novo PMP2 mutations in families with type 1 Charcot-Marie-Tooth disease.
Forsythiaside A Exhibits Anti-inflammatory Effects in LPS-Stimulated BV2 Microglia Cells Through Activation of Nrf2/HO-1 Signaling Pathway.
Immunopathology of multiple sclerosis.
Group exercise training for balance, functional status, spasticity, fatigue and quality of life in multiple sclerosis: a randomized controlled trial.
Pharmacokinetics of dalfampridine extended release 7.5-mg tablets in healthy subjects and individuals with mild and moderate renal impairment: An open-label study.
Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group.
A novel neuroprotective mechanism of riluzole: direct inhibition of protein kinase C.
Information on natalizumab (marketed as Tysabri)
Disease Modifying Drugs in Multiple Sclerosis: Mechanisms of Action and New Drugs in the Horizon.
Proton Density MRI Increases Detection of Cervical Spinal Cord Multiple Sclerosis Lesions Compared with T2-Weighted Fast Spin-Echo.
Tocilizumab, MS, and NMOSD.
Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS] (RECYCLINE)
Solitary sclerosis: Progressive neurological deficit from a spatially isolated demyelinating lesion: A further report.
The initiation and prevention of multiple sclerosis.
Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia.
Multiple sclerosis: Risk of comorbid inflammatory diseases in MS might not be genetically determined.
Patients feeling severely affected by multiple sclerosis: How do patients want to communicate about end-of-life issues?
Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis.
In vitro screening of NADPH oxidase inhibitors and in vivo effects of L-leucinethiol on experimental autoimmune encephalomyelitis-induced mice.

Pages